Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
8.93
-0.24 (-2.62%)
Dec 11, 2025, 2:04 PM EST - Market open
Tango Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts that cover Tango Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $12.5, which forecasts a 39.98% increase in the stock price over the next year. The lowest target is $10 and the highest is $15.
Price Target: $12.5 (+39.98%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Tango Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 5 |
| Buy | 3 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +67.97% | Dec 4, 2025 |
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Nov 18, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $8 → $14 | Strong Buy | Maintains | $8 → $14 | +56.77% | Nov 18, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $10 → $12 | Strong Buy | Maintains | $10 → $12 | +34.38% | Oct 24, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $11 | Buy | Initiates | $11 | +23.18% | Aug 19, 2025 |
Financial Forecast
Revenue This Year
64.37M
from 42.07M
Increased by 53.01%
Revenue Next Year
16.90M
from 64.37M
Decreased by -73.75%
EPS This Year
-0.91
from -1.19
EPS Next Year
-1.24
from -0.91
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 70.8M | 70.8M | ||||
| Avg | 64.4M | 16.9M | ||||
| Low | 61.1M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 68.2% | 9.9% | ||||
| Avg | 53.0% | -73.8% | ||||
| Low | 45.3% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.86 | -1.18 | ||||
| Avg | -0.91 | -1.24 | ||||
| Low | -0.98 | -1.29 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.